ResMed Inc.
As of Oct 22, 2026, ResMed is in Stage 2, the uptrend phase, now in week 3 (since Oct 8, 2026). It closed at $253.06, 7.5% below its 52-week high and above its 200-day average, which is falling.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 18 in Medical Instruments & Supplies · #1 of 272 in Health Care
Is RMD early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RMD among Medical Instruments & Supplies28th of 51 by relative strength
All 51 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | PLSE | Stage 2 · wk 34 | 98 | +1.3% |
| 2 | PDEX | Stage 2 · wk 36 | 97 | −13.3% |
| 3 | HBIO | Stage 2 · wk 11 | 95 | +3.6% |
| 4 | ATRC | Stage 2 · wk 10 | 89 | −1.1% |
| 5 | WST | Stage 2 · wk 24 | 82 | +4.8% |
| 6 | BDX | Stage 2 · wk 11 | 81 | +9.8% |
| 7 | ICUI | Stage 3 · wk 1 | 81 | +3.1% |
| 8 | OSUR | Stage 3 · wk 8 | 75 | −4.8% |
| …28 | RMD | Stage 2 · wk 3 | 50 | +13.8% |
ResMed: quick answers
What stage is ResMed in?
As of Oct 22, 2026, ResMed (RMD) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 8, 2026 and is in week 3. What the four stages mean
Is ResMed in an uptrend?
Yes. ResMed is in a Stage 2 uptrend. It trades 12.9% above its 200-day average, which is falling.
How far is ResMed from its 52-week high?
ResMed closed at $253.06 on Oct 22, 2026, 7.5% below its 52-week high of $273.72. Its 52-week low is $182.30.
How has ResMed performed over the past year?
As of Oct 22, 2026, ResMed is down 4.7% over the past year and up 4.2% so far in 2026.
Which sector and industry is ResMed in?
ResMed is in the Medical Instruments & Supplies industry, part of the Health Care sector.
About this companyHealth Care· Medical Instruments & Supplies
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.